From ESC: Statin Nonadherence, LDL Cholesterol Lowering After Acute MI, Ablation Therapy for Atrial Fibrillation, Advances in Cardiac Amyloidosis, and more
Shownotes
Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2026 European Society of Cardiology Congress. Hosted by JAMA Executive Editor Gregory Curfman, MD, with JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editors Gregg C. Fonarow, MD, and Paz Tayal, BMBCh, PhD. Related Content:
- Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%
- LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation
- Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence
- Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant
- 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis
- Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy
- Low-Voltage Ablation in Persistent Atrial Fibrillation
- Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy
- Artificial Intelligence–Enabled Acquisition and Interpretation for Screening Aortic Stenosis
- Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy
- Causal Endotype–Based Classification of Myocardial Infarction
- Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy
- Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan
- Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer